{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:47:28Z","timestamp":1790668048589,"version":"4.1.0"},"reference-count":38,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DDDT"],"DOI":"10.2147\/dddt.s240865","type":"journal-article","created":{"date-parts":[[2021,5,2]],"date-time":"2021-05-02T23:00:06Z","timestamp":1619996406000},"page":"1811-1817","source":"Crossref","is-referenced-by-count":7,"title":["The Application of Zonisamide to Patients Suffering from Dementia with Lewy Bodies: Emerging Clinical Data"],"prefix":"10.2147","volume":"Volume 15","author":[{"given":"Babak","family":"Tousi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James JB","family":"Leverenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,5]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"McKeith","year":"2017","journal-title":"Neurology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-017-0478-x","volume":"19","author":"Tousi","year":"2017","journal-title":"Curr Treat Options Neurol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1002\/mds.22322","volume":"23","author":"Goldman","year":"2008","journal-title":"Mov Disord"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.parkreldis.2019.12.005","volume":"76","author":"Murata","year":"2020","journal-title":"Parkinsonism Relat Disord"},{"key":"ref5","unstructured":"U.S. Food and Drug Administration. Zonisamide approvable labeling [Internet]. Approved labeling text; 2000. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2000\/20789lbl.pdf. Accessed April 20, 2021."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/0920-1211(93)90011-U","volume":"15","author":"Schmidt","year":"1993","journal-title":"Epilepsy Res"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.seizure.2004.04.015","volume":"13","author":"Seino","year":"2004","journal-title":"Seizure"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12147","author":"Verrotti","year":"2013","journal-title":"Acta Neurol Scand"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1212\/01.wnl.0000250236.75053.16","volume":"68","author":"Murata","year":"2007","journal-title":"Neurology"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1111\/j.1468-2982.2006.01191.x","volume":"26","author":"Ashkenazi","year":"2006","journal-title":"Cephalalgia"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1097\/WNF.0b013e318225140c","volume":"34","author":"Mohammadianinejad","year":"2011","journal-title":"Clin Neuropharmacol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1111\/j.1742-1241.2007.01365.x","volume":"61","author":"Kinrys","year":"2007","journal-title":"Int J Clin Pract"},{"key":"ref13","author":"Zesiewicz","year":"2007","journal-title":"Mov Disord"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s00702-004-0107-1","volume":"111","author":"Gluck","year":"2004","journal-title":"J Neural Transm"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.parkreldis.2007.05.008","volume":"14","author":"Miwa","year":"2008","journal-title":"Parkinsonism Relat Disord"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/8626783","volume":"2018","author":"Nishijima","year":"2018","journal-title":"Parkinsons Dis"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0920-1211(95)00078-X","volume":"22","author":"Okada","year":"1995","journal-title":"Epilepsy Res"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.expneurol.2009.11.018","volume":"221","author":"Sonsalla","year":"2010","journal-title":"Exp Neurol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.neuropharm.2009.05.005","volume":"57","author":"Yamamura","year":"2009","journal-title":"Neuropharmacology"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/ana.21885","volume":"67","author":"Asanuma","year":"2010","journal-title":"Ann Neurol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.expneurol.2009.11.002","volume":"221","author":"Costa","year":"2010","journal-title":"Exp Neurol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/jnc.13116","volume":"134","author":"Sano","year":"2015","journal-title":"J Neurochem"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0168-0102(01)00298-X","volume":"41","author":"Murata","year":"2001","journal-title":"Neurosci Res"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.3233\/JAD-161068","volume":"56","author":"Matsunaga","year":"2017","journal-title":"J Alzheimers Dis"},{"key":"ref25","unstructured":"Dainippon Sumitomo Pharma Co. Parkinson\u2019s disease drug \u201cTRERIEF\u201d obtained manufacturing and marketing approval [Internet]; 2009. Available from: https:\/\/www.ds-pharma.com\/ir\/news\/2009\/20090121.html. Accessed April 20, 2021."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1002\/mds.27372","volume":"33","author":"Fox","year":"2018","journal-title":"Mov Disorders"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/j.1440-1819.2010.02075.x","volume":"64","author":"Odawara","year":"2010","journal-title":"Psychiatry Clin Neurosci"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"e664","DOI":"10.1212\/WNL.0000000000005010","volume":"90","author":"Murata","year":"2018","journal-title":"Neurology"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Movement Disorder Society Task Force on Rating Scales for Parkinson\u2019s Disease. The Unified Parkinson\u2019s Disease Rating Scale (UPDRS): status and recommendations. Mov Disord. 2003;18(7):738\u2013750.","DOI":"10.1002\/mds.10473"},{"key":"ref30","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1212\/WNL.44.12.2308","volume":"44","author":"Cummings","year":"1994","journal-title":"Neurology"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/j.1440-1819.1997.tb03199.x","volume":"51","author":"Arai","year":"1997","journal-title":"Psychiatry Clin Neurosci"},{"key":"ref33","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.92.15_supplement.P4.1-011","volume":"92","author":"Toya","year":"2019","journal-title":"Neurology"},{"key":"ref34","author":"Hasegawa","year":"2020","journal-title":"J Alzheimers Dis"},{"key":"ref35","unstructured":"Sumitomo Dainippon Pharma Co. Sumitomo dainippon pharma obtains approval in Japan for TRERIEF, a therapeutic agent for Parkinson\u2019s disease, for an additional indication of Parkinsonism in dementia with Lewy bodies [Internet]; 2018. Available from: https:\/\/www.ds-pharma.com\/ir\/news\/2018\/20180702.html. Accessed April 20, 2021."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s13760-019-01132-4","volume":"119","author":"Kaur","year":"2019","journal-title":"Acta Neurol Belg"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1002\/mds.26286","volume":"30","author":"Murata","year":"2015","journal-title":"Mov Disord"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/ncn3.12026","volume":"4","author":"Murata","year":"2016","journal-title":"Neurol Clin Neurosci"}],"container-title":["Drug Design, Development and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=69003","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=69003","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T01:41:08Z","timestamp":1724982068000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/the-application-of-zonisamide-to-patients-suffering-from-dementia-with-peer-reviewed-fulltext-article-DDDT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":38,"URL":"https:\/\/doi.org\/10.2147\/dddt.s240865","relation":{},"ISSN":["1177-8881"],"issn-type":[{"value":"1177-8881","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5]]}}}